Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BNGO 
Bionano Genomics Inc (BNGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: BNGO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -76.92% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.03M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 171359 | Beta 2.09 | 52 Weeks Range 2.68 - 72.60 | Updated Date 04/22/2025 |
52 Weeks Range 2.68 - 72.60 | Updated Date 04/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -88.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -11.19% |
Management Effectiveness
Return on Assets (TTM) -32.76% | Return on Equity (TTM) -170.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9488000 | Price to Sales(TTM) 0.39 |
Enterprise Value 9488000 | Price to Sales(TTM) 0.39 | ||
Enterprise Value to Revenue 0.31 | Enterprise Value to EBITDA -0.18 | Shares Outstanding 3007000 | Shares Floating 2825708 |
Shares Outstanding 3007000 | Shares Floating 2825708 | ||
Percent Insiders 0.07 | Percent Institutions 9.3 |
Analyst Ratings
Rating 3 | Target Price 60 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bionano Genomics Inc
Company Overview
History and Background
Bionano Genomics Inc. was founded in 2003. Initially focused on nanochannel technology, it evolved to specialize in optical genome mapping (OGM) for structural variation analysis. Its key milestones include the development and commercialization of the Saphyr system and its expanding applications in cytogenetics and cancer research.
Core Business Areas
- Optical Genome Mapping (OGM): Bionano's core business revolves around its Saphyr system, which uses OGM to provide comprehensive structural variation analysis. This includes the sale of instruments, consumables, and related services to research institutions, clinical labs, and pharmaceutical companies.
Leadership and Structure
Bionano Genomics Inc. is led by Erik Holmlin, PhD, President and CEO. The company has a functional organizational structure with departments focused on research and development, sales and marketing, manufacturing, and operations.
Top Products and Market Share
Key Offerings
- Saphyr System: Saphyr is Bionano's primary platform for OGM. It detects structural variations in DNA that are often missed by traditional methods like karyotyping and FISH. Market share data is evolving, but adoption is increasing in research and clinical settings. Competitors include PacBio (PACB) for long-read sequencing, and traditional cytogenetics methods offered by various vendors.
Market Dynamics
Industry Overview
The genomics market is rapidly expanding, driven by advancements in sequencing technologies and increased demand for personalized medicine. Structural variation analysis is a growing segment within genomics.
Positioning
Bionano positions itself as a leader in OGM, offering a unique solution for comprehensive structural variation analysis that complements existing sequencing and cytogenetic methods. Its competitive advantage lies in its high-resolution mapping capabilities.
Total Addressable Market (TAM)
The estimated TAM for structural variation analysis is significant, potentially reaching billions of dollars as OGM becomes more widely adopted. Bionano is positioned to capture a growing share of this market with its Saphyr system.
Upturn SWOT Analysis
Strengths
- Unique OGM technology
- High-resolution structural variation analysis
- Growing adoption in research and clinical settings
- Strong intellectual property portfolio
Weaknesses
- Limited market penetration compared to sequencing
- High cost of Saphyr system
- Reliance on a single platform
- Financial losses and need for continued funding
Opportunities
- Expanding applications of OGM in cancer research and diagnostics
- Partnerships with pharmaceutical companies
- Development of new assays and workflows
- Increased adoption of OGM in clinical genetics
Threats
- Competition from alternative technologies (e.g., long-read sequencing)
- Slow adoption by clinicians and researchers
- Regulatory hurdles for clinical applications
- Economic downturn affecting research budgets
Competitors and Market Share
Key Competitors
- Pacific Biosciences of California, Inc. (PACB)
- Illumina, Inc. (ILMN)
- Thermo Fisher Scientific Inc. (TMO)
Competitive Landscape
Bionano's competitive advantage lies in its OGM technology, which offers unique capabilities for structural variation analysis. However, it faces competition from established players in the sequencing market like Illumina and PacBio.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Bionano has experienced rapid revenue growth in recent years, driven by increased adoption of OGM.
Future Projections: Analysts project continued revenue growth for Bionano as OGM becomes more widely adopted, but profitability is uncertain.
Recent Initiatives: Recent initiatives include expanding the applications of OGM, developing new assays, and forming partnerships with key opinion leaders and pharmaceutical companies.
Summary
Bionano Genomics is a company with innovative OGM technology that has promising applications, particularly in structural variation analysis. However, the company faces challenges including profitability, competition from established players, and the need for continued funding. While revenue growth has been strong, the company's long-term success depends on increasing adoption of OGM and achieving profitability. Investors should carefully weigh the potential rewards against the risks.
Similar Companies
ILMN
Illumina Inc
ILMN
Illumina Inc
PACB
Pacific Biosciences of California
PACB
Pacific Biosciences of California
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Company Press Releases
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. Investing in Bionano Genomics Inc. involves risks, including the risk of loss of capital.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bionano Genomics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2018-08-21 | President, CEO & Director and CFO Dr. Robert Erik Holmlin M.B.A., Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 98 | Website https://www.bionano.com |
Full time employees 98 | Website https://www.bionano.com | ||
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. The company offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. It also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic data from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, the company offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.